111 related articles for article (PubMed ID: 23080486)
1. Unusual substitutions in HIV-1 vif from children infected perinatally without progression to AIDS for more than 8 years without therapy.
De Maio FA; Rocco CA; Aulicino PC; Bologna R; Mangano A; Sen L
J Med Virol; 2012 Dec; 84(12):1844-52. PubMed ID: 23080486
[TBL] [Abstract][Full Text] [Related]
2. Effect of HIV-1 Vif variability on progression to pediatric AIDS and its association with APOBEC3G and CUL5 polymorphisms.
De Maio FA; Rocco CA; Aulicino PC; Bologna R; Mangano A; Sen L
Infect Genet Evol; 2011 Aug; 11(6):1256-62. PubMed ID: 21571098
[TBL] [Abstract][Full Text] [Related]
3. APOBEC3-mediated editing in HIV type 1 from pediatric patients and its association with APOBEC3G/CUL5 polymorphisms and Vif variability.
De Maio FA; Rocco CA; Aulicino PC; Bologna R; Mangano A; Sen L
AIDS Res Hum Retroviruses; 2012 Jun; 28(6):619-27. PubMed ID: 22145963
[TBL] [Abstract][Full Text] [Related]
4. Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.
Kikuchi T; Iwabu Y; Tada T; Kawana-Tachikawa A; Koga M; Hosoya N; Nomura S; Brumme ZL; Jessen H; Pereyra F; Trocha A; Walker BD; Iwamoto A; Tokunaga K; Miura T
J Virol; 2015 May; 89(9):4992-5001. PubMed ID: 25717111
[TBL] [Abstract][Full Text] [Related]
5. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the nef and vif genes associated with progression to AIDS in elite controller and slow-progressor patients.
Cruz NV; Amorim R; Oliveira FE; Speranza FA; Costa LJ
J Med Virol; 2013 Apr; 85(4):563-74. PubMed ID: 23417613
[TBL] [Abstract][Full Text] [Related]
7. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
Wang J; Shaban NM; Land AM; Brown WL; Harris RS
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
[TBL] [Abstract][Full Text] [Related]
8. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
9. Codon pairs of the HIV-1 vif gene correlate with CD4+ T cell count.
Bizinoto MC; Yabe S; Leal É; Kishino H; Martins Lde O; de Lima ML; Morais ER; Diaz RS; Janini LM
BMC Infect Dis; 2013 Apr; 13():173. PubMed ID: 23578255
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child.
Alexander L; Aquino-DeJesus MJ; Chan M; Andiman WA
J Virol; 2002 Oct; 76(20):10533-9. PubMed ID: 12239333
[TBL] [Abstract][Full Text] [Related]
11. HIV-2 Vif Diversity Among Defective and Nondefective Sequences.
Bertine M; Visseaux B; Storto A; Collin G; Matheron S; Descamps D; Charpentier C;
J Acquir Immune Defic Syndr; 2016 May; 72(1):e9-e11. PubMed ID: 26689972
[No Abstract] [Full Text] [Related]
12. Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals.
Fourati S; Malet I; Binka M; Boukobza S; Wirden M; Sayon S; Simon A; Katlama C; Simon V; Calvez V; Marcelin AG
AIDS; 2010 Sep; 24(15):2313-21. PubMed ID: 20729708
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Escape from Small-Molecule Antagonism of Vif.
Sharkey M; Sharova N; Mohammed I; Huff SE; Kummetha IR; Singh G; Rana TM; Stevenson M
mBio; 2019 Feb; 10(1):. PubMed ID: 30808702
[TBL] [Abstract][Full Text] [Related]
14. Characterization of human immunodeficiency virus type 1 vif gene in long-term asymptomatic individuals.
Hassaïne G; Agostini I; Candotti D; Bessou G; Caballero M; Agut H; Autran B; Barthalay Y; Vigne R
Virology; 2000 Oct; 276(1):169-80. PubMed ID: 11022005
[TBL] [Abstract][Full Text] [Related]
15. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G.
Sawyer SL; Emerman M; Malik HS
PLoS Biol; 2004 Sep; 2(9):E275. PubMed ID: 15269786
[TBL] [Abstract][Full Text] [Related]
16. [Progress in the study of HIV-1 Vif and related inhibitors].
Li ZY; Zhan P; Liu XY
Yao Xue Xue Bao; 2010 Jun; 45(6):684-93. PubMed ID: 20939174
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 subtype variability in Vif derived from molecular clones affects APOBEC3G-mediated host restriction.
Lisovsky I; Schader SM; Sloan RD; Oliveira M; Coutsinos D; Bernard NF; Wainberg MA
Intervirology; 2013; 56(4):258-64. PubMed ID: 23689841
[TBL] [Abstract][Full Text] [Related]
19. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action.
Santa-Marta M; Aires da Silva F; Fonseca AM; Rato S; Goncalves J
Mol Immunol; 2007 Jan; 44(4):583-90. PubMed ID: 16580072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
